Dear colleagues,
We are planning to stimulate human derived B lymphocyte (CLL cells) in our lab. We would like to understand the role of activating the B-cell receptor (BCR) signalling in the cross-talk between the CLL cells and tissue microenvironment after a drug treatment. According to the literature and as far as I know, immobilised anti-IgM acts more effective compared with soluble antibody in activation of B cells.
I did a literature search and contacted different companies about immobilised anti-IgM, but I couldn't find any related product for my experiment.
Your advice or suggestions will be much appreciated.
Many thanks in advance.
Best Wishes
Erhan Aptullahoglu
Northern Institute for Cancer Research, UK
Your advice or suggestions will be much appreciated
Activation of B cells either via surface IgD or surface IgM does not require that the antibody be bound to any carrier. However, it is found in some publications that the author has fixed the antibody on the surface of the culture well, but without ever showing the effectiveness of such a practice. In fact the use of a good anti-IgM (or a good anti-IgD) is more than enough. And it is also valid for any other surface molecule: b2M, CD44, CD71,107B5,117F10 ... and even for the CD40 in some cases (G28.5).
Jean-Jacques Pin Thank you very much for your answer. Really helpful. Best Wishes
- Badges
- Science topic